



Leading Cannabinoid Patient Care in Canada

Corporate Presentation | July 2017

TSXV: CMM

OTCQB: CAMDF

Forward Looking Statements

Except for historical information, this presentation contains forward-looking statements, which reflect Canabo Medical Inc.'s (Canabo) current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo's actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this presentation are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this presentation represent views only as of the date of this presentation and are presented for the purpose of assisting potential investors in understanding Canabo's business, and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.





Canabo Medical Inc. wholly owns and operates CMC Clinics, the largest chain of referral only Medical Marijuana Clinics in Canada

- 23 operating clinics nation-wide
- 20 operating partner clinics
- Over 65 licensed physicians
- Over 20 licensed partner physicians
- Over 20,000 patients seen since inception
- No patient fee
- We accept referrals only – no walk-ins
- Not a dispensary
- Proprietary physician training program
- Proprietary cannabinoid educator training program, for introducing new patients to the nuances of cannabinoid treatments
- National call center efficiently manages patient schedules for all clinics
- Physicians see patients only in reference to medical marijuana treatments, not the underlying condition



Canadian Leading Cannabinoid Team



Dr. Neil Smith

Executive Chairman

Dr. Smith is a leading Otolaryngologist Head and Neck Surgeon currently working in the Halifax/Dartmouth area. He is also a founder and principal of a sleep apnea company with 14 clinic locations throughout Atlantic Canada.



John Philpott

President & CEO

Mr. Philpott has been active in the medical industry for the past two decades, serving as CEO of a leading North American physician recruitment firm. His background includes management and consulting assignments relating to clinic operational efficiencies in a wide variety of hospital, clinic and medical research operations.



Dr. Danial Schechter

CMC Co-Founder

Dr. Schechter is Co-Founder of the Canabo Clinics and a practicing family physician. After studying and working alongside some of Canada's leading medical marijuana researchers, Dr. Schechter has quickly become recognized as a leading expert in the field and is a frequent guest speaker.



Garry Stewart

CFO

Mr. Stewart has enjoyed a thirty year career in accounting, and has experience as CFO and Vice President Finance with both public and private companies including TAR Investments Limited and Datarite Limited. He has obtained his CPA, CMA, FCPA and FCMA designations and is a member of CPA Nova Scotia and CPA Canada.

Additional Board Members:

- Ian Klassen – Public market management experience in the natural resource and technology industries
- Alistair MacLennan – Experienced director with +25 years in capital markets




Occurrence in Canada of Conditions Treatable by Medicinal Marijuana

	Pain Disorders				Psychiatric Disorders		Neurological Disorders			Cancer/Gastrointestinal	
	Chronic Pain	Arthritis	Migraines	Fibromyalgia	Anxiety Disorders	Insomnia	Parkinson's	Epilepsy	MS	Cancer (New Patients/Year)	Crohn's
Patient Base	2,769,400	4,801,390	2,707,400	800,000	1,208,374	4,087,146	550,536	213,242	100,000	191,300	236,936

Source of Condition Occurrence: Stats Canada

Areas of Treatment at Canabo Clinics

- Pain Disorders
- Psychiatric Disorders
- Neurological Disorders
- Cancer/Gastrointestinal
- Other



17.4 million treatable conditions in Canada

The total number of Medical Marijuana eligible patients in Canada is less than the presenting conditions, as some potential patients present with multiple conditions



Canabo Has Three Primary Revenue Sources



- **Patient – Physician consultation**

Fees for the patient interaction are fully recoverable from the Provincial Health Departments. Our partner clinics operate the same, and the patients seen there are included in our research databases.



- **Database Subscriptions**

Canabo maintains a complete database on all patients, including medical, market demographics and treatment efficacy. Canabo generates revenue by offering access to our data via annual subscriptions and one-off analysis assignments.




- **Independent Medical Evaluation Consulting**

Canabo provides consulting to the insurance and employer industries, providing expert opinion on the appropriateness of cannabinoid treatment or workplace safety issues on a fee for service basis.



Clinic Footprint



We currently have 18 open clinics in:

- Toronto
- Barrie
- Ottawa
- Stoney Creek
- Burlington
- Halifax
- London
- Chilliwack
- St. Catherine's
- St. John's
- Edmonton
- Calgary
- Hamilton
- Sackville
- Kingston
- Wolfville
- Owen Sound
- Kelowna

Q3 planned openings for clinics in:

- Saint John
- Vernon
- Vancouver
- Victoria
- Winnipeg

We have 20 partner clinics including:

- Calgary
- Okotoks
- High River
- Edmonton
- Strathmore
- Red Deer
- Medicine Hat
- London

How the Partner System Works

- CMClinic partner physicians and educators will be trained at all partner clinics
- Increased efficiencies through lower start-up capital costs
- Partner clinics are shareholders, meaning their objectives are aligned with ours



CMM Growing Impact

2016 Year End

- 10 Clinics
- 0 Partner Clinics

Revenue / Net Income:

- \$2,000,000 / -
\$1,400,000

Avg New Patients per month:

- 300 actual

Value of Cannabis Purchased by CMM Patients per year:

- \$11,500,000

2017 Year End

- 24 Clinics
- 30 Partner Clinics

Revenue / Net Income:

- \$8,500,000 /
\$1,200,000

Avg New Patients per month:

- 1,200 estimated
- +1,000 current actual

Value of Cannabis Purchased by CMM Patients per year:

- \$64,000,000

2018 Year End

- 30 Clinics
- 40 Partner Clinics

Revenue / Net Income:



- \$14,000,000 /
\$4,700,000

Avg New Patients per month:

- 1,700 estimated

Value of Cannabis Purchased by CMM Patients per year:

- \$98,000,000



Valuation

Recent Financing

- December invested \$8.4 Million Q1-2017
- \$1.40 per share
- Representing \$42 Million pre-money valuation

Q2 Valuation

- \$31,500,000 Market Cap
- \$22,000,000 Enterprise Value

PUBLICLY TRADED CANNABIS COMPANIES - CANADA				
NAME	DATE	# PATIENTS	MRK CAP	PATIENTS/ MRK CAP
Aphria	Dec 16	12,000	986M	82,166
Aurora Cannabis	May 17	13,600	935M	68,750
Cannimed	Apr 17	14,000	222M	15,857
Canopy Growth	Mar 17	55,000	1.37B	24,909
OrganiGram	Apr 17	4000	312M	78,000
Canabo	July 17	21,000	16M	762



Capital Structure:

Common Shares Issued:	36,358,350
Options and Warrants:	1,987,070
Escrow Shares (at listing)	13,765,500
Total Fully Diluted Shares	38,345,420



Contact Information:

Neil Smith
Executive Chairman

John Philpott
President & CEO

info@cmclinic.ca
www.canabocorp.com

